Sodium benzoate for treatment of hepatic encephalopathy

Gastroenterology and Hepatology

Volumn 9, Issue 4, 2013, Pages 219-227

  Misel, Michael L ^a   Gish, Robert G ^b   Patton, Heather ^b   Mendler, Michel ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ammonia; Hepatic encephalopathy; Hippurate; Hyperammonemia; Lactulose; Rifaximin; Sodium benzoate; Urea cycle

Indexed keywords

4 PHENYLBUTYRIC ACID; AMMONIA; ASCORBIC ACID; BENZOIC ACID; ENEMA; GLUTAMINE; GLYCEROL PHENYLBUTYRATE; LACTULOSE; ORNITHINE PHENYLACETATE; PENICILLIN DERIVATIVE; PHENYLACETIC ACID; PROBENECID; RIFAXIMIN; SODIUM;

AMMONIA BLOOD LEVEL; AMMONIA FORMATION; ANGIONEUROTIC EDEMA; ARTICLE; ASCITES; BURNING SENSATION; DEHYDRATION; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROENCEPHALOGRAM; EPIGASTRIC DISCOMFORT; FLATULENCE; FLUID RESUSCITATION; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION RATE; HEADACHE; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; HYPERNATREMIA; HYPONATREMIA; MENTAL HEALTH; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; MOOD CHANGE; NAUSEA; NEUROMUSCULAR FUNCTION; PATIENT COMPLIANCE; PATIENT SAFETY; PROTEIN RESTRICTION; QUALITY OF LIFE; SODIUM BLOOD LEVEL; STOMACH DISCOMFORT; STOMACH DISTENSION; TINNITUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UREA CYCLE; URTICARIA; VERTIGO; VOMITING;

EID: 84878435117     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Blei AT, Cordoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-1976. (Pubitemid 32660887)
2. Amodio P, Del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol. 2001;35:37-45. (Pubitemid 32646222)
3. Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382-1389.
4. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549-559. (Pubitemid 46450607)
5. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38:3552-3555. (Pubitemid 44908490)
6. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515-525.
7. Butterworth RF, Giguere JF, Michaud J, et al. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol. 1987;6:1-12.
8. Windmueller HG, Spaeth AE. Uptake and metabolism of plasma glutamine by the small intestine. J Biol Chem. 1974;249:5070-5079.
9. Castell DO, Moore EW. Ammonia absorption from the human colon. The role of nonionic diffusion. Gastroenterology. 1971;60:33-42.
10. Wright G, Noiret L, Olde Damink SW, et al. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 2011;31:163-175.
11. Clay AS, Hainline BE. Hyperammonemia in the ICU. Chest. 2007;132:1368-1378. (Pubitemid 47621016)
12. Schiano TD. Treatment options for hepatic encephalopathy. Pharmacotherapy. 2010;30:16S-21S.
13. Cash WJ, McConville P, McDermott E, et al. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM. 2010;103:9-16.
14. Kramer L, Tribl B, Gendo A, et al. Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology. 2000;31:30-34. (Pubitemid 30033685)
15. Abdel-Khalek EE, El-Fakhry A, Helaly M, et al. Systemic inflammatory response syndrome in patients with liver cirrhosis. Arab J Gastroenterol. 2011;12:173-177.
16. Felipo V, Urios A, Montesinos E, et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis. 2012;27:51-58.
17. Miyake Y, Yasunaka T, Ikeda F, et al. SIRS score reflects clinical features of non-acetaminophen-related acute liver failure with hepatic coma. Intern Med. 2012;51:823-828.
18. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347-3357.
19. Bunchman TE, Barletta GM, Winters JW, et al. Phenylacetate and benzoate clearance in a hyperammonemic infant on sequential hemodialysis and hemofiltration. Pediatr Nephrol. 2007;22:1062-1065. (Pubitemid 46881929)
20. Uribe M, Campollo O, Vargas F, et al. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology. 1987;7:639-643. (Pubitemid 17130704)
21. Horsmans Y, Solbreux PM, Daenens C, et al. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther. 1997;11:165-170. (Pubitemid 27067349)
22. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26:1410-1414. (Pubitemid 27520004)
23. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci. 2000;45:1549-1552.
24. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.
25. Phongsamran PV, Kim JW, Cupo Abbott J, et al. Pharmacotherapy for hepatic encephalopathy. Drugs. 2010;70:1131-1148.
26. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13:109-118. (Pubitemid 23187314)
27. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double dummy study versus lactulose. Eur J Clin Res. 1993;4:7-18. (Pubitemid 24090540)
28. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51-58. (Pubitemid 36078524)
29. Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57-66.
30. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52:737-741.
31. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46:399-407. (Pubitemid 40959882)
32. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
33. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther. 2007;26:1147-1161. (Pubitemid 47480963)
34. Nettis E, Colanardi MC, Ferrannini A, et al. Sodium benzoate-induced repeated episodes of acute urticaria/angio-oedema: randomized controlled trial. Br J Dermatol. 2004;151:898-902. (Pubitemid 39482128)
35. Ravicti [package insert]. South San Francisco, CA: Hyperion Therapeutics; 2013.
36. Jalan R, Wright G, Davies NA, et al. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses. 2007;69:1064-1069. (Pubitemid 47430227)
37. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther. 2012;92:321-331.
38. Lizardi-Cervera J, Almeda P, Guevara L, et al. Hepatic encephalopathy: a review. Ann Hepatol. 2003;2:122-130.
39. Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag. 2009;5:617-626.
40. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001;138:S46-S54.
41. Uribe M, Bosques F, Poo J, et al. A double-blind randomized trial of sodium benzoate vs. lactulose in patients with chronic portal systemic encephalopathy. Hepatology. 1988;8:1449.
42. Spustova V, Gajdos M, Opatrny KJ, et al. Serum hippurate and its excretion in conservatively treated and dialysed patients with chronic renal failure. Physiol Res. 1991;40:599-606.
43. Sushma S, Dasarathy S, Tandon RK, et al. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992;16:138-144.
44. Efrati C, Masini A, Merli M, et al. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution. Am J Gastroenterol. 2000;95:3574-3578.
45. Campollo O, Gil S, Olvera G, et al. Efficacy and safety of sodium benzoate for the long-term treatment of chronic hyperammonemic hepatic encephalopathy. Hepatology. 1992;16:248A.
46. Mendenhall CL, Rouster S, Marshall L, et al. A new therapy for portal systemic encephalopathy. Am J Gastroenterol. 1986;81:540-543. (Pubitemid 16097218)
47. Shih VE. Alternative-pathway therapy for hyperammonemia. N Engl J Med. 2007;356:2321-2322. (Pubitemid 46849164)
48. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. Crit Care Clin. 2005;21:S1-S8. (Pubitemid 41446381)
49. Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol. 2011;55:426-434.
50. Ryder KW, Olson JF, Kahnoski RJ, et al. Hyperammonemia after transurethral resection of the prostate: a report of 2 cases. J Urol. 1984;132:995-997. (Pubitemid 14023526)
51. Beliveau GP, Brusilow SW. Glycine availability limits maximum hippurate synthesis in growing rats. J Nutr. 1987;117:36-41. (Pubitemid 17031432)
52. Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr Treat Options Gastroenterol. 2006;9:464-474. (Pubitemid 44803668)
53. Environmental Protection Agency (EPA). Basic information about benzene in drinking water. http://water.epa.gov/drink/contaminants/basicinformation/ benzene.cfm#four. Accessed February 28, 2013.
54. Hassanein T, Blei AT, Perry W, et al. Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol. 2009;104:1392-1400.
55. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721. (Pubitemid 34183979)